BioSpace News Archive

Pharm Country

Merck to Showcase Oncology Pipeline Amid Concerns About Dependence on Keytruda

While Merck’s Keytruda has racked up nearly 20 approvals from the U.S. Food and Drug Administration, there is some investor concern that the company is too dependent on the product for its future.

June 19, 2019
·
3 min read
·
Alex Keown
Drug Development

Ironwood and Allergan’s Linzess Successful in Easing Irritable Bowel Syndrome Symptoms

The drug showed a statistically significant and clinically meaningful improvement in overall abdominal symptoms compared to placebo for all primary and secondary endpoints.

June 19, 2019
·
2 min read
·
Mark Terry
Biotech Beach

Denovo Biopharma Acquires Global Rights to Experimental Alzheimer’s Drug

Denovo’s new asset will target the Alpha2C adrenoceptor.

June 19, 2019
·
2 min read
·
Alex Keown
Business

Ultragenyx and Arcturus Therapeutics Expand Existing Research Collaboration and License Agreement to Develop Additional Nucleic Acid Therapies for Rare Diseases

Scope of the collaboration expands to include up to 12 rare disease targets and includes Arcturus nucleic acid technologies to enable mRNA, DNA, and siRNA therapeutics

June 19, 2019
·
8 min read
Drug Development

Bavarian Nordic Initiates Phase 3 Trial of Freeze-dried MVA-BN® Smallpox Vaccine

Bavarian Nordic A/S announced the initiation of a pivotal Phase 3 trial of the freeze-dried formulation of MVA-BN® smallpox vaccine in 1,110 healthy, vaccinia-naïve subjects.

June 19, 2019
·
4 min read
Business

Comet Therapeutics Earns $28.5 Million Series A with Sight Set on Metabolic Diseases

Comet has set up shop in Kendall Square with about 10 employees. The company has plans to expand to at least double that amount over the next year as it moves from the preclinical phase to the clinical phase.

June 19, 2019
·
3 min read
·
Alex Keown
Business

Gilead Strikes $2.48 Billion Deal with Nurix to Focus on Protein Degradation

The focus will be on discovering drugs that use the body’s natural protein control processes.

June 19, 2019
·
3 min read
·
Mark Terry
Drug Development

Polyphor announces enrollment of first patient in FORTRESS Phase III clinical trial for balixafortide in combination with eribulin in patients with metastatic breast cancer

Balixafortide is the most advanced and only CXCR4 antagonist in development in a pivotal Oncology global registration trial.

June 19, 2019
·
5 min read
Pharm Country

Audacity Therapeutics Selected to Participate at Upcoming Cavendish BioHealth Impact Forum

Forum uniquely brings together leading family offices, foundations and impact investors seeking impact investment, grant-giving, and philanthropy opportunities within health and the life sciences

June 19, 2019
·
4 min read
Policy

Looking to Prevail in Court, Catalyst Takes on the FDA in Battle Over LEMS Treatment

Lawsuits against the FDA are fairly common. However, winning the lawsuit will be a tough road for Catalyst, as other pharma companies that challenged the regulatory agency learned.

June 19, 2019
·
4 min read
·
Alex Keown